Developer docs
API playgroundTry for free, no card

Search company profiles

Libella Gene Therapeutics

Full company profile

uuid0029nq6

Namestring
Libella Gene Therapeutics
Company typeenum
Private
Founded yearstring
-
Ownership categoryenum
akta.pro rankint
HeadquartersManhattan, United States
HQ citystring
Manhattan
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
gene therapy treatments, genetic medicine therapeutics, DNA-based therapeutics, biotechnology research, regenerative gene medicine
Industry1 code
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Gene Therapy
No data
Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Libella Gene Therapeutics develops gene therapy treatments aimed at addressing diseases through genetic-medicine interventions. The company has obtained full regulatory approval in Vanuatu, enabling it to deliver therapeutic gene-based products within that jurisdiction as a for-profit private entity.

Differentiator
Functional benefit
Problem solved
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Market position
Competitive moat1 record

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Libella Gene Therapeutics

Libella Gene Therapeutics firmographics

Firmographics
Name
Libella Gene Therapeutics
Website
https://libellagenetherapeutics.com
Company type
Private
Ownership category
akta.pro rank

Libella Gene Therapeutics industry classification

Industry
Product category
Gene Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Gene therapy treatments
  • Genetic medicine therapeutics
  • DNA-based therapeutics
  • Biotechnology research
  • Regenerative gene medicine

Where Libella Gene Therapeutics is headquartered

Location

Headquarters

HQ city
Manhattan
HQ country
United States
HQ region
North America

Markets served

Libella Gene Therapeutics business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Libella Gene Therapeutics product offering

Product offering

Core offering

Libella Gene Therapeutics develops gene therapy treatments aimed at addressing diseases through genetic-medicine interventions. The company has obtained full regulatory approval in Vanuatu, enabling it to deliver therapeutic gene-based products within that jurisdiction as a for-profit private entity.

Differentiator

Problem solved

Functional benefit

Companies that use Libella Gene Therapeutics

Customer profile

Ideal customer profiles1 record

Libella Gene Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Libella Gene Therapeutics partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights2 records

Libella Gene Therapeutics competitors and assessment

Company assessment

Market position

Competitive moat1 record

Key risks4 records

Key highlights4 records

Customer concentration

Libella Gene Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Libella Gene Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

Libella Gene Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Libella Gene Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Libella Gene Therapeutics

What does Libella Gene Therapeutics do?

Libella Gene Therapeutics develops gene therapy treatments aimed at addressing diseases through genetic-medicine interventions. The company has obtained full regulatory approval in Vanuatu, enabling it to deliver therapeutic gene-based products within that jurisdiction as a for-profit private entity.

When was Libella Gene Therapeutics founded?

Libella Gene Therapeutics was founded in -1.

Where is Libella Gene Therapeutics based?

Libella Gene Therapeutics is headquartered in Manhattan, United States, in the North America region.

Does Libella Gene Therapeutics have an API?

No public API is recorded for Libella Gene Therapeutics.

What industry is Libella Gene Therapeutics in?

Libella Gene Therapeutics's product category is Gene Therapy. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MIT Technology ReviewBuyer beware of this $1 million gene therapy for agingLibella Gene Therapeutics is offering an unproven telomere-extending gene therapy for $1 million per dose at a clinic in Colombia, bypassing US FDA approval. Experts and ethics researchers have raised significant concerns regarding the treatment's safety risks, particularly cancer potential, and the questionable conduct of the so-called 'pay-to-play' clinical trial.PR NewswireNew Clinical Study May Be the World's First Cure for Alzheimer's DiseaseLibella Gene Therapeutics LLC announced it will conduct an outside-the-US clinical trial in Cartagena, Colombia, using gene therapy to reverse Alzheimer's disease by inducing telomerase to lengthen telomeres in the body's cells. The trial, led by scientist Dr. Bill Andrews and scheduled to begin in Q1 2018 at MediHelp Services Clinic, will be supported by LATAM Market Access Inc., which is providing clinical study design, regulatory support, and project management services. The company cited faster approval times and lower costs in Colombia compared to traditional US clinical trials, with the therapy based on technology exclusively licensed from Sierra Sciences.PR NewswireLibella Gene Therapeutics Announces Experimental Research Project in Hopes of Reversing Alzheimer'sLibella Gene Therapeutics announced an experimental research project using gene therapy to treat Alzheimer's disease by lengthening telomeres, with plans to begin in the coming weeks. The study will be conducted in partnership with MediHelp in Cartagena, Colombia, and will offer approximately 50 treatment spots over the next 12 months. The company claims its gene therapy delivery system has demonstrated safety in over 186 prior clinical trials.